An Assessment of the Steady-State Pharmacokinetic and Pharmacodynamic Profile of Tysabri 300 mg Following at Least 12 Monthly Infusions
Phase of Trial: Phase IV
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen Idec
- 01 May 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2008 New trial record.